Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Return on Capital Employed (2016 - 2025)

Bioadaptives' Return on Capital Employed history spans 7 years, with the latest figure at 47.79% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 948.0% to 47.79% in Q4 2025 year-over-year; TTM through Dec 2025 was 47.79%, a 948.0% increase, with the full-year FY2025 number at 49.34%, up 1032.0% from a year prior.
  • Return on Capital Employed hit 47.79% in Q4 2025 for Bioadaptives, down from 81.33% in the prior quarter.
  • Over the last five years, Return on Capital Employed for BDPT hit a ceiling of 81.33% in Q3 2025 and a floor of 10.57% in Q2 2023.
  • Historically, Return on Capital Employed has averaged 35.66% across 5 years, with a median of 33.22% in 2021.
  • Biggest five-year swings in Return on Capital Employed: tumbled -3439bps in 2023 and later skyrocketed 6555bps in 2025.
  • Tracing BDPT's Return on Capital Employed over 5 years: stood at 59.01% in 2021, then tumbled by -51bps to 28.99% in 2022, then crashed by -49bps to 14.92% in 2023, then soared by 157bps to 38.31% in 2024, then grew by 25bps to 47.79% in 2025.
  • Business Quant data shows Return on Capital Employed for BDPT at 47.79% in Q4 2025, 81.33% in Q3 2025, and 81.2% in Q2 2025.